October 2025 FDA Recall Duloxetine by Breckenridge Pharmaceutical, Inc.
D-0100-2026 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Breckenridge Pharmaceutical, Inc. on October 9, 2025 for the product Duloxetine. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0100-2026

Reason for Recall
CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
Initiated
10-09-2025
Reported
11-05-2025
Quantity
172,263 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Breckenridge Pharmaceutical, Inc.
Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51991-748-90), b.)1000-count bottle (NDC 51991-748-10),Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain; Dist. by: Breckenridge Pharmaceutical, Inc., Berkeley Heights, NJ 07922.

Batch or Lot Expiration Information

Lot# 90-count-
Lot# 240721C; Exp. 02/28/2027 1000-count-
Lot# 230286C; Exp.02/28/2026